In a study of some 500 patients, the safety and efficacy of the antidepressant Cymbalta® on the core anxiety symptoms in patients with generalized anxiety disorder was evaluated. Findings of the said study showed that Cymbalta® significantly reduced core anxiety symptoms and associated painful physical symptoms and improved functional impairment associated with the illness.
In this nine-week study, Cymbalta® significantly improved core anxiety symptoms such as anxious mood, fears and tension by 51 percent in patients taking 60mg/day and by 50 percent in patients taking 120mg/day compared to an improvement of 32 percent in patients taking sugar pill. Patients taking both 60mg/day and 120mg/day had significantly greater response and remission rates compared to patients taking sugar pill. In addition, Cymbalta significantly reduced overall pain by 41 percent and 37 percent respectively, compared to 16 percent in patients taking sugar pill. Cymbalta patients also reported greater improvement in quality of life as measured by the Sheehan Disability Scale, Quality of Life Enjoyment and Satisfaction Questionnaire and European Quality of Life 5 Dimensions, including improved ability to perform everyday activities at work, home, and in social situations compared to sugar pill.
These results was announced in presentations at the March 25 Annual Conference of the Anxiety Disorders Association of America (ADAA).
Source: Lilly Newsroom
Comment Preview